Under his leadership, Incyte filed over fifteen Investigational New Drug (IND) applications, contributing to the company's robust pipeline of innovative therapies. Before joining Incyte in 2018, Dr. Dhanak was Vice President and Global Head of Discovery Sciences at Johnson & Johnson's Janssen Research & Development group where he led efforts in drug discovery and development. He also spent 25 years at GlaxoSmithKline, culminating in his role as Vice President and Head of the Cancer Epigenetics Discovery Performance Unit where he advanced research in cancer treatments. Dr. Dhanak holds a B.Sc. in Chemistry from the University of Manchester Institute of Science and Technology and a Ph.D. from the University of London. He completed his postdoctoral research in Natural Product Synthesis at Northwestern University.